Shandong Buchang Pharmaceutical Co., Ltd.’s progress announcement on matters related to the company’s planned purchase of Angong Niuhuang Pill pharmaceutical production technology
Securities code: 603858 Securities abbreviation: Buchang Pharmaceutical Announcement number: 2025-217
Shandong Buchang Pharmaceutical Co., Ltd.
Announcement on the progress of the company’s plan to purchase Angong Niuhuang Pill pharmaceutical production technology
The company's board of directors and all directors guarantee that the contents of this announcement do not contain any false records, misleading statements or major omissions, and assume legal responsibility for the authenticity, accuracy and completeness of its contents.
1. Transaction Overview
Shandong Buchang Pharmaceutical Co., Ltd. (hereinafter referred to as the "Company" or "Buchang Pharmaceutical") held the 34th meeting of the fourth board of directors on April 14, 2023, and reviewed and approved the "Proposal on Matters Related to the Company's Plan to Purchase the Pharmaceutical Production Technology of Angong Niuhuang Pills". According to the actual needs of the company's development strategy and in order to enrich the company's products, the company plans to transfer the Angong Niuhuang Pill pharmaceutical production technology owned by Liaoning Hancaotang Traditional Chinese Medicine Co., Ltd. (hereinafter referred to as "Liaoning Hancaotang") for 8.4 million yuan. For details, please refer to the "Announcement on Matters Related to the Company's Plan to Purchase the Pharmaceutical Production Technology of Angong Niuhuang Pills" disclosed by the company on the website of the Shanghai Stock Exchange (www.sse.com.cn) on April 15, 2023 (announcement number: 2023-056).
On April 21, 2023, the company and Liaoning Hancaotang officially signed the "Technical Contract for Change of Drug Marketing Authorization Holder and Change of Drug Production Site". For details, please refer to the "Progress Announcement on Matters Related to the Company's Plan to Purchase the Drug Production Technology of Angong Niuhuang Pills" disclosed on the website of the Shanghai Stock Exchange (www.sse.com.cn) on April 22, 2023 (announcement number: 2023-058).
"Technical Contract for Change of Drug Marketing Authorization Holder and Change of Drug Production Site" because the contract name did not meet the requirements for technology contract filing, the company revised the contract name to "Drug Marketing Authorization (Drug Approval Number) Technology Transfer Contract". On January 19, 2024, the company signed the "Angong Niuhuang Pill Drug Marketing Authorization (Drug Approval Number) Technology Transfer Contract Supplementary Agreement" with relevant parties. For details, please refer to the "Announcement on Signing a Supplementary Agreement to the Technology Transfer Contract" disclosed by the company on the website of the Shanghai Stock Exchange (www.sse.com.cn) on January 20, 2024 (Announcement No.: 2024-007).
Due to changes in the supply price of cultivated Niuhuang Pills and the design needs of the outer packaging of Angong Niuhuang Pills, after joint and friendly consultations, on June 4, 2024, the company and relevant parties signed the "Supplementary Agreement to the Supplementary Agreement for the Drug Marketing Authorization (Drug Approval Number) Technology Transfer Contract of Angong Niuhuang Pills" signed in January 2024. For details, please refer to the "Announcement on Signing a Supplementary Agreement to the Technology Transfer Contract" disclosed by the company on the website of the Shanghai Stock Exchange (www.sse.com.cn) on June 5, 2024 (announcement number: 2024-072).
In March 2025, the company received the "Drug Supplementary Application Approval Notice" for Angong Niuhuang Pills approved and issued by the State Food and Drug Administration, agreeing to change the marketing license holder of Angong Niuhuang Pills from Liaoning Hancaotang to Buchang Pharmaceutical. For details, please refer to the "Progress Announcement on Matters Related to the Company's Plan to Purchase the Pharmaceutical Production Technology of Angong Niuhuang Pills" disclosed by the company on the website of the Shanghai Stock Exchange (www.sse.com.cn) on March 19, 2025 (announcement number: 2025-055).
2. Progress of this transaction
Recently, according to the announcement on the website of the State Food and Drug Administration, the company completed the registration change of production site of Angong Niuhuang Pills. The relevant information is now disclosed as follows:
Generic name of the drug: Angong Niuhuang Pills
Drug approval number/API registration number: National Drug Approval Number Z21021982
Marketing authorization holder: Shandong Buchang Pharmaceutical Co., Ltd.
Address of marketing authorization holder: No. 369, Zhonghua West Road, Mudan District, Heze City, Shandong Province
Manufacturer's name: Shandong Buchang Pharmaceutical Co., Ltd.
Production enterprise address: No. 1818, Zhonghua West Road, Heze City
Filing content: The drug production site of Angong Niuhuang Pills has been changed. The production site has been changed from Liaoning Hancaotang Traditional Chinese Medicine Co., Ltd. "No. 15 Hongsheng Street, Xishi District, Yingkou City" to Shandong Buchang Pharmaceutical Co., Ltd. "No. 1818 Zhonghua West Road, Heze City". The product prescription, process, execution standards, etc. remain unchanged, and the drug instructions and labels have been revised. Registration authority: Shandong Provincial Food and Drug Administration
Filing date: 2025-11-18
Registration number: Lu Bei 2025051088
3. Other conditions of drugs
Angong Niuhuang Pills are mainly used to clear away heat and detoxify, soothe convulsions and rejuvenate the mind. It is used for febrile disease, pericardial pathogens, febrile convulsions, coma and delirium; stroke, coma, encephalitis, meningitis, toxic encephalopathy, cerebral hemorrhage, and septicemia with the above syndromes.
According to Minai.com data, the annual sales trend of sample hospitals in China (urban public, county-level public, urban community, township health) shows that the annual sales of Angong Niuhuang Pills from 2022 to 2024 are 230.76 million yuan, 241.39 million yuan, and 268.94 million yuan; the annual sales trend of China's urban brick-and-mortar pharmacies shows that the annual sales of Angong Niuhuang Pills from 2022 to 2024 are 457,394 yuan. million, 5,381.9 million yuan and 4,422.07 million yuan.
As of the date of this announcement, the company has invested approximately RMB 11.9655 million in research and development expenses for Angong Niuhuang Pills.
4. Impact on listed companies and risk warnings
The change of the production site of Angong Niuhuang Pills is conducive to expanding the company's business, enriching the company's product line, and strengthening market competitiveness, and will not have a significant impact on the company's current production and operations. The specific future sales of drugs may be affected by industry policies, market environment changes and other factors, and are uncertain. Investors are kindly requested to make prudent decisions and pay attention to preventing investment risks.
Announcement is hereby made.
Board of Directors of Shandong Buchang Pharmaceutical Co., Ltd.
November 22, 2025